Multidrug-resistant tuberculosis: Treatment and outcomes of 93 patients

Canadian Respiratory Journal

Volumn 22, Issue 2, 2015, Pages 97-102

  Brode, Sarah K ^a,b   Varadi, Robert ^a,b   McNamee, Jane ^a   Malek, Nina ^a   Stewart, Sharon ^a   Jamieson, Frances B ^b   Avendano, Monica ^a,b  

^a WEST PARK HEALTHCARE CENTRE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Multidrug resistant tuberculosis; Outcomes; Review; Treatment

Indexed keywords

TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; COUGHING; FEMALE; FEVER; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER; PRIORITY JOURNAL; SPUTUM CULTURE; WEIGHT REDUCTION; ANTIBIOTIC RESISTANCE; ETHNOLOGY; MIDDLE AGED; ONTARIO; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; ONTARIO; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84926162648     PISSN: 11982241     EISSN: 19167245     Source Type: Journal    
DOI: 10.1155/2015/359301     Document Type: Article

References (33)

1. Zignol M, Hosseini M, Wright A, et al. Global incidence of multidrug-resistant tuberculosis. J Infec Dis 2006;194:479-85.
2. Banerjee R, Allen J, Westenhouse J, et al. Extensively drug-resistant tuberculosis in California: 1993-2006. Clin Infect Dis 2008;47:450-7.
3. Migliori G, Sotgiu G, Lange C, et al. Extensively drug-resistant tuberculosis: Back to the future. Eur Respir J 2010;36:476-7.
4. World Health Organization. Global Tuberculosis Report 2012. (Accessed November 15, 2012).
5. Langlois-Klassen D, Wooldrage K, Manfreda J, et al. Piecing the puzzle together: Foreign-born tuberculosis in an immigrant receiving country. Eur Respir J 2011;38:895-902.
6. Public Health Agency of Canada. Tuberculosis in Canada, 2011. (Accessed November 15, 2012).
7. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: Emergency update 2008. Geneva: World Health Organization, 2008.
8. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva: World Health Organization, 2011.
9. Caminero JA. Treatment of multidrug-resistant tuberculosis: Evidence and controversies. Int J Tuberc Lung Dis 2006;10:829-37.
10. Franke MF, Appleton SC, Mitnick CD, et al. Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis 2013;56:770-6.
11. Clinical and Laboratory Standards Institute (CLSI). Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: Approved standard, 2nd edn. CLSI document M24-A2. Wayne: Clinical Laboratory Standards Institute, 2011.
12. NCCLS. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: Approved standard. Document M24-A. Wayne: NCCLS, 2003.
13. NCCLS. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes, 2nd edn-Tentative standard. NCCLS document M24-T2. Wayne: NCCLS, 2000.
14. Torun T, Gungor G, Ozmen I, et al. Side effects associated with the treatment of multi-drug resistant tuberculosis. Int J Tuberc Lung Dis 2005;9:1372-7.
15. Roberts CH, Smith C, Breen R, et al. Hepatotoxicity in the treatment of tuberculosis using moxifloxacin-containing regimens. Int J Tuberc Lung Dis 2011;15:1275-6.
16. Keshavjee S, Gelmanova IY, Shin SS, et al. Hepatotoxicity during treatment for multidrug-resistant tuberculosis: Occurrence, management and outcome. Int J Tuberc Lung Dis 2012;16:596-603.
17. Seddon JA, Godfrey-Fausset P, Jacobs K, et al. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J 2012;40:1277-86.
18. Satti H, Mafukidze A, Jooste PL, et al. High rate of hypothyroidism among patients treated for multidrug-resistant in Lesotho. Int J Tuberc Lung Dis 2012;16:468-72.
19. Toczek A, Cox H, Du Cros P, et al. Strategies for reducing treatment default in drug-resistant tuberculosis: Systematic review and meta-analysis. Int J Tuberc Lung Dis 2012;17:299-307.
20. World Health Organization. Definitions and reporting framework for tuberculosis: 2013 revision. Geneva: 2013.
21. Hersi A, Elwood K, Cowie R, et al. Multidrug-resistant tuberculosis in Alberta and British Columbia, 1989 to 1998. Can Respir J 1999;6:155-60.
22. Avendano M, Goldstein RS. Multidrug-resistant tuberculosis: Long term follow-up of 40 non-HIV-infected patients. Can Respir J 2000;7:383-9.
23. Minion J, Gallant V, Wolfe J, Jamieson F. Multidrug and extensively drug-resistant tuberculosis in Canada 1997-2008: Demographic and disease characteristics. PLoS One 2013;8:e53466.
24. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004;169:1103-9.
25. Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: A systematic review and meta-analysis. PLoS One 2009;4:e6914.
26. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: An individual patient data meta-analysis of 9,153 patients. PLoS Med 2012;9:e1001300.
27. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003;3:432-42.
28. Orenstein EW, Basu S, Shan NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: Systematic review and meta-analysis. Lancet Infect Dis 2009;9:153-61.
29. Beiser M. Resettling refugees and safeguarding their mental health: Lessons learned from The Refugee Resettlement Project. Transcultural Psychiatry 2009:46;539-83.
30. Mckenzie K, Hansson E, Tuck A, Lam J, Jackson F. Improving mental health services for immigrant, refugee, ethno-cultural and racialized groups; issues and options for service improvement. Toronto: Centre for Addiction and Mental Health, and Mental Health Commission of Canada, 2009.
31. Achar JM, Sherpa T, Cohen HW, et al. Differences in clinical presentation among persons with pulmonary tuberculosis: A comparison of documented and undocumented foreign-born versus US-born persons. Clin Inf Dis 2008;47:1277-83.
32. Dey T, Bridgen G, Cox H, et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: A systematic review and meta-analysis J Antimicrob Chemother 2013;68:284-93.
33. Gopal M, Padayatchi N, Metcalfe JZ, et al. Systematic review of clofazimine for the treatment of drug resistant tuberculosis. Int J Tuberc Lung Dis 2013;17:1001-7.